Terlipressin vs Octreotide in Acute Variceal Bleeding

Mortality Benefit

The American Association for the Study of Liver Diseases recommends terlipressin as the only vasoactive agent demonstrated to reduce bleeding-related mortality (RR 0.66, 95% CI 0.49-0.88) compared to placebo in meta-analyses 1

No significant differences in 5-day or 42-day rebleeding rates between terlipressin and octreotide are found in meta-analyses, according to the European Association for the Study of the Liver 1

Terlipressin is associated with hyponatremia and myocardial ischemia due to coronary vasoconstriction, as reported by the American College of Gastroenterology 1
Octreotide is associated with nausea/vomiting, abdominal pain, and headache, as well as hyperglycemia and hypoglycemia, according to the American Gastroenterological Association 1

The initial dose of terlipressin is 2 mg IV every 4 hours for the first 48 hours, and the maintenance dose is 1 mg IV every 4 hours after bleeding is controlled, as recommended by the European Association for the Study of the Liver 1, 2
The initial dose of octreotide is 50 μg IV bolus, and the maintenance dose is 50 μg/hour continuous IV infusion, according to the American Association for the Study of Liver Diseases 1, 2

The American College of Gastroenterology recommends starting vasoactive therapy immediately when variceal bleeding is suspected, even before endoscopic confirmation 1, 2

The European Association for the Study of the Liver recommends that neither terlipressin nor octreotide should be used as monotherapy, and that all patients require vasoactive drug therapy, endoscopic variceal ligation within 12 hours, and prophylactic antibiotics simultaneously 1, 2

The American Gastroenterological Association advises against delaying vasoactive therapy waiting for endoscopy, and recommends starting immediately upon clinical suspicion 1, 2
A restrictive transfusion strategy should be maintained, with hemoglobin levels between 7-9 g/dL, unless massive hemorrhage or cardiovascular comorbidities are present, as recommended by the American Association for the Study of Liver Diseases 2

The American Gastroenterological Association recommends that octreotide is the preferred vasoactive drug for acute variceal bleeding due to its superior safety profile with comparable efficacy to terlipressin 3
Meta-analyses show no significant differences between terlipressin and octreotide in terms of mortality, hemostasis, early rebleeding, late rebleeding, blood transfusion requirements, and hospital stay 3
Terlipressin was found to be less effective than octreotide in terms of bleeding control within 24 hours in a systematic review and meta-analysis involving 3344 patients from 30 RCTs 3

Adverse events are 2.39-fold higher in patients receiving terlipressin compared to octreotide or somatostatin 3
Terlipressin is associated with significantly more adverse events including abdominal pain, chest pain, diarrhea, and hyponatremia 3, 4
Octreotide's main side effects include hypoglycemia, hyperglycemia, bradycardia, and rare cases of pancreatitis 3, 5

The standard dosing regimen for octreotide is an initial 50 μg IV bolus, followed by continuous IV infusion at 50 μg/hour 3, 5
The standard dosing regimen for terlipressin is an initial 2 mg IV every 4 hours until bleeding is controlled, then 1 mg IV every 4 hours for maintenance 3, 4

The American College of Radiology recommends that prophylactic antibiotics should be administered along with vasoactive therapy to reduce mortality, bacterial infections, and rebleeding 6, 4
Combination therapy with vasoactive drugs and endoscopy has become the favored treatment algorithm in managing acute bleeding from esophageal varices 7, 6

Terlipressin is contraindicated in patients experiencing hypoxia, worsening respiratory symptoms, or ongoing coronary, peripheral, or mesenteric ischemia 3
Octreotide may require insulin dosage adjustment due to potential effects on blood glucose levels 3, 5

The FDA has not approved terlipressin for variceal bleeding in the United States, while octreotide is available and commonly used 3, 5